Haemonetics (HAE) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)
Haemonetics (HAE) Net Income towards Common Stockholders Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.70 Bn | 194.09 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 129.93 Bn | 126.46 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 120.49 Bn | 111.27 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 74.60 Bn | 74.06 Bn | 3.85 Bn | 51.47% |
| 5 | Edwards Lifesciences | 52.68 Bn | 48.42 Bn | 1.35 Bn | -7.83% |
| 6 | Dexcom | 34.78 Bn | 32.84 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 33.83 Bn | 31.72 Bn | 2.18 Bn | 11.15% |
| 8 | Koninklijke Philips | 26.44 Bn | 23.12 Bn | 4.55 Bn | 1,825.47% |
| 9 | Steris | 23.18 Bn | 22.69 Bn | 684.20 Mn | 17.54% |
| 10 | Haemonetics | 4.93 Bn | 4.70 Bn | 202.80 Mn | -7.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | -7.04% |
| Mar 28, 2026 | -38.98% |
| Dec 27, 2025 | 10.74% |
| Sep 27, 2025 | 5.27% |
| Jun 28, 2025 | 19.67% |
| Mar 29, 2025 | 81.23% |
| Dec 28, 2024 | 17.40% |
| Sep 28, 2024 | 31.66% |
| Jun 29, 2024 | 119.78% |
| Mar 30, 2024 | 56.71% |
| Dec 30, 2023 | -0.67% |
| Sep 30, 2023 | -19.67% |
| Jul 1, 2023 | 57.45% |
| Apr 1, 2023 | 18.63% |
| Dec 31, 2022 | 3.29% |
| Oct 1, 2022 | -4.01% |
| Jul 2, 2022 | 63.17% |
| Apr 2, 2022 | -22.35% |
| Jan 1, 2022 | 8.29% |
| Oct 2, 2021 | -7.52% |